H.R. 919

119th Congress

In Committee

Chronic Disease Flexible Coverage Act

Sponsored byRepublican:Rep. Buchanan, Vern [R-FL-16]FL· Introduced 4 février 2025

2

Cosponsors

10

Actions

0

Amendments

2

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Received in the Senate and Read twice and referred to the Committee on Finance.

5 mars 2025·1 year ago

Summary

Introduced in House · Updated 7 mars 2025

Chronic Disease Flexible Coverage Act

This bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold.

Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold. 

The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to include

  • angiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease;
  • anti-resorptive therapy for individuals with osteoporosis or osteopenia;
  • beta-blockers for individuals with congestive heart failure or coronary artery disease;
  • blood pressure monitors for individuals with hypertension;
  • inhaled corticosteroids and peak flow meters for individuals with asthma;
  • insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes;
  • international normalized ratio testing for individuals with liver disease or bleeding disorders;
  • low-density lipoprotein testing for individuals with heart disease;
  • statins for individuals with heart disease or diabetes; and
  • selective serotonin reuptake inhibitors for individuals with depression. 

The bill provides statutory authority for the IRS's guidance. 

Timeline

10 actions

  1. Received in the Senate and Read twice and referred to the Committee on Finance.

    5 mars 2025 · IntroReferral

  2. DEBATE - The House proceeded with forty minutes of debate on H.R. 919.

    4 mars 2025 · Floor

  3. Considered under suspension of the rules. (consideration: CR H964-966)

    4 mars 2025 · Floor

  4. Mr. Smith (MO) moved to suspend the rules and pass the bill.

    4 mars 2025 · Floor

  5. Motion to reconsider laid on the table Agreed to without objection.

    4 mars 2025 · Floor

  6. Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H964)

    4 mars 2025 · Floor

  7. On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H964)

    4 mars 2025 · Floor

  8. Referred to the House Committee on Ways and Means.

    4 février 2025 · IntroReferral

  9. Introduced in House

    4 février 2025 · IntroReferral

  10. Introduced in House

    4 février 2025 · IntroReferral

Sponsorship

2 cosponsors

Sponsor

Republican:Rep. Buchanan, Vern [R-FL-16]FL

Cosponsors

  • Democrat150%
  • Republican150%

Classification

Policy area

Taxation

Legislative subjects

Health care costs and insuranceHealth care coverage and accessHealth promotion and preventive careIncome tax deductions

Committees

2

  • Ways and Means Committee

    House · Standing

    • Referred To4 Feb 2025
  • Finance Committee

    Senate · Standing

    • Referred To5 Mar 2025

Cosponsor momentum

Cumulative over time

Cosponsors grew from 1 on 4 février 2025 to 2 on 3 mars 2025.

Pelosi Tracker
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.